Cingulate Inc.
CING- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001862150
No open-market purchases or sales by Cingulate Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $9.88M in total; no superinvestor holds it.
Other share classesCINGW
Q1 2023 vs. Q4 2022
How the institutions holding Cingulate Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 11 | 13 | +2 |
| Shares | 112.4K | 438.8K | +326.4K (+290.4%) |
| Value | $112.1K | $433.0K | +$320.9K (+286.3%) |
New holders (5)
Institutions that held Cingulate Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Group Inc | 123,016 | $121.2K | 0.00% |
| Geode Capital Management, LLC | 105,021 | $103.4K | 0.00% |
| Prime Capital Investment Advisors, LLC | 48,262 | $47.5K | 0.00% |
| State Street Corp | 44,760 | $44.1K | 0.00% |
| Mercer Global Advisors Inc | 31,369 | $31.0K | 0.00% |
Sold out (3)
Institutions that held Cingulate Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Sabby Management, LLC | 22,018 | $22.0K |
| Bank of America Corp | 20 | $20 |
| Morgan Stanley | 19 | $19 |